Developmental History, Clinical Considerations, and Future Perspectives
How is ipilumumab best used in the treatment of melanoma? Current and planned clinical trials combine ipilimumab with chemotherapy, other immunotherapy, radiotherapy, and targeted therapy.
Intralesional Therapy for Metastatic Melanoma
For metastatic melanoma, this direct therapeutic injection into a lesion was put on the map by a 1975 story in Cancer. Why is it still relevant?
How Zelboraf (Vemurafenib), a New FDA-Approved Therapy, Extends Life for Patients With Metastatic Melanoma
In this issue of The Melanoma Letter, Dr. Paul Chapman discusses the exciting, newly FDA-approved drug Zelboraf, which targets a unique mutation in the BRAF gene common among patients with advanced melanoma.
Vemurafenib and Ipilimumab to Be Tried Together
With two new approved treatments for metastatic melanoma, each of which improves overall survival, physicians will have options for single or combined therapy.
Melanoma Screening Saves Lives
The risk of dying from skin cancer is directly related to the depth of the cancer and the amount of time it has been growing unnoticed.
The "Ugly Duckling" Sign: An Early Melanoma Recognition Tool For Clinicians and the Public
Trying to distinguish melanoma from other nevi can pose a challenge for clinicians and patients.
First Evidence: Targeted Melanoma Therapy May Change the Landscape of Treatment
Metastatic melanoma continues to be largely refractory to available therapies. Can targeted therapy change that?